How to buy 9 Meters Biopharma stock

9 Meters Biopharma is a business based in the US. 9 Meters Biopharma shares (INNT) are listed on the NASDAQ and all prices are listed in US Dollars. 9 Meters Biopharma employs 8 staff and has a market cap (total outstanding shares value) of 0.00.

9 Meters Biopharma stock price (NASDAQ: INNT)

Use our graph to track the performance of INNT stocks over time.

9 Meters Biopharma shares at a glance

• Key figures

Information last updated 2021-01-23.

52-week range	$0.00 - $0.00
50-day moving average more info button	$0.73
200-day moving average more info button	$0.61
Wall St. target price	$10.00
PE ratio more info button	N/A
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$-0.49

Buy 9 Meters Biopharma stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy 9 Meters Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

9 Meters Biopharma financials

Gross profit TTM	$0
Return on assets TTM	-193.21%
Return on equity TTM	0%
Profit margin	0%
Book value	$0.14
Market capitalisation more info button	$23.1 million

TTM: trailing 12 months

9 Meters Biopharma share dividends

We're not expecting 9 Meters Biopharma to pay a dividend over the next 12 months.

Have 9 Meters Biopharma's shares ever split?

9 Meters Biopharma's shares were split on a 1:10 basis on 1 February 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 9 Meters Biopharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for 9 Meters Biopharma shares which in turn could have impacted 9 Meters Biopharma's share price.

9 Meters Biopharma share price volatility

Over the last 12 months, 9 Meters Biopharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 9 Meters Biopharma's is -0.5435. This would suggest that 9 Meters Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, 9 Meters Biopharma has bucked the trend.

9 Meters Biopharma overview

9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products.

Frequently asked questions

What percentage of 9 Meters Biopharma is owned by insiders or institutions?
Currently 10.237% of 9 Meters Biopharma shares are held by insiders and 2.733% by institutions. How many people work for 9 Meters Biopharma?
Latest data suggests 8 work at 9 Meters Biopharma. When does the fiscal year end for 9 Meters Biopharma?
9 Meters Biopharma's fiscal year ends in December. Where is 9 Meters Biopharma based?
9 Meters Biopharma's address is: 8480 Honeycutt Road, Raleigh, NC, United States, 27615 What is 9 Meters Biopharma's ISIN number?
9 Meters Biopharma's international securities identification number is: US6544051096 What is 9 Meters Biopharma's CUSIP number?
9 Meters Biopharma's Committee on Uniform Securities Identification Procedures number is: 61174L501